|
Chronic Pain Modulation of Mesolimbic Dopamine Signaling for Natural and Opiate Rewards |
1F31DA056200-01 |
|
NIDA |
2022 |
|
Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness |
1K02DA054304-01A1 |
|
NIDA |
2022 |
|
Role of disability and pain in opioid overdose: mechanism and risk mitigation |
1R01DA053243-01A1 |
|
NIDA |
2022 |
|
Impact of Medicare Part D opioid safety policies on disabled beneficiaries before and during the COVID-19 pandemic |
1R01DA055131-01 |
|
NIDA |
2022 |
|
Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability |
1R01DA057568-01 |
|
NIDA |
2022 |
|
Social determinants of substance use disorder treatment outcomes in a vulnerable population |
1R21DA055229-01 |
|
NIDA |
2022 |
|
A pilot study of ambulatory Heart Rate Variability Biofeedback for substance use disorder |
1R21DA056468-01 |
|
NIDA |
2022 |
|
Wearable sensor for opioids detection based on electrochemical sensor arrayintegrated with Bluetooth device |
2R44DA051289-02 |
|
NIDA |
2022 |
|
Systems biology of RNA Modifications in HIV/AIDS and Substance Use Disorders |
3R01DA046170-05S1 |
|
NIDA |
2022 |
|
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity |
3R01DA046204-05S1 |
|
NIDA |
2022 |